Bristol Myers Squibb Company $BMY Shares Sold by Jones Financial Companies Lllp

Jones Financial Companies Lllp reduced its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 21.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 114,590 shares of the biopharmaceutical company’s stock after selling 32,121 shares during the period. Jones Financial Companies Lllp’s holdings in Bristol Myers Squibb were worth $6,989,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the business. Pinney & Scofield Inc. purchased a new stake in Bristol Myers Squibb in the fourth quarter valued at $25,000. Park Square Financial Group LLC purchased a new stake in shares of Bristol Myers Squibb in the fourth quarter worth about $26,000. Global Wealth Strategies & Associates grew its holdings in Bristol Myers Squibb by 137.5% during the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 275 shares during the period. Harel Insurance Investments & Financial Services Ltd. purchased a new position in Bristol Myers Squibb during the first quarter valued at approximately $31,000. Finally, Accent Capital Management LLC acquired a new position in Bristol Myers Squibb in the first quarter valued at approximately $33,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on BMY shares. Morgan Stanley reaffirmed a “hold” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Citigroup dropped their price target on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating on the stock in a research report on Friday, August 1st. Daiwa America downgraded shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 5th. Daiwa Capital Markets lowered shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 target price on the stock. in a research note on Tuesday, August 5th. Finally, Wall Street Zen lowered Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 6th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $56.38.

Bristol Myers Squibb Price Performance

Shares of Bristol Myers Squibb stock opened at $47.25 on Wednesday. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11. The business has a 50 day simple moving average of $47.09 and a two-hundred day simple moving average of $50.36. The stock has a market capitalization of $96.17 billion, a P/E ratio of 19.05, a PEG ratio of 2.39 and a beta of 0.35. Bristol Myers Squibb Company has a 12 month low of $42.96 and a 12 month high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, topping the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The firm had revenue of $12.27 billion during the quarter, compared to analysts’ expectations of $11.32 billion. During the same period in the previous year, the business earned $2.07 earnings per share. The firm’s revenue for the quarter was up .6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. As a group, analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd were given a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.2%. The ex-dividend date was Thursday, July 3rd. Bristol Myers Squibb’s dividend payout ratio is 100.00%.

Insider Buying and Selling at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 56,000 shares of the business’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the transaction, the executive vice president directly owned 167,379 shares in the company, valued at approximately $7,922,048.07. The trade was a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.07% of the company’s stock.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.